Treatment of giant cell arteritis;Traitement de la maladie de Horton

Revue de Medecine Interne

Volumn 34, Issue 7, 2013, Pages 431-437

  Sailler, L ^a   Pugnet, G ^a   Bienvenu, B ^b  

^a CHU PURPAN   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Giant cell arteritis; Hydroxychloroquine; Methotrexate; Tocilizumab; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; CORTICOSTEROID; DAPSONE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; TOCILIZUMAB;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CORTICOSTEROID SPARING ACTIVITY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GIANT CELL ARTERITIS; HUMAN; ISCHEMIA; LOW DRUG DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RISK BENEFIT ANALYSIS; SHORT SURVEY; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; DISEASE PROGRESSION; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; PREDNISONE; WITHHOLDING TREATMENT;

EID: 84879604684     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2013.02.032     Document Type: Short Survey

References (63)

1. Barrier J.H. Treatment of giant cell arteritis. Ann Med Interne (Paris) 1994, 145:533-537.
2. Kyle V. Treatment of polymyalgia rheumatica/giant cell arteritis. Baillieres Clin Rheumatol 1991, 5:485-491.
3. Salvarani C., Cantini F., Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008, 372:234-245.
4. Hunder G.G., Sheps S.G., Allen G.L., Joyce J.W. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 1975, 82:613-618.
5. Delecoeuillerie G., Joly P., Cohen de Lara A., Paolaggi J.B. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11year survey of 210patients). Ann Rheum Dis 1988, 47:733-739.
6. Lundberg I., Hedfors E. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. J Rheumatol 1990, 17:1340-1345.
7. Rouster-Stevens K.A., Gursahaney A., Ngai K.L., Daru J.A., Pachman L.M. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 2008, 59:222-226.
8. Hill M.R., Szefler S.J., Ball B.D., Bartoszek M., Brenner A.M. Monitoring glucocorticoid therapy: a pharmacokinetic approach. Clin Pharmacol Ther 1990, 48:390-398.
9. Hayreh S.S., Zimmerman B., Kardon R.H. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002, 80:355-367.
10. Hayreh S.S., Zimmerman B. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica 2003, 217:239-259.
11. Hayreh S.S. Acute retinal arterial occlusive disorders. Prog Retin Eye Res 2011, 30:359-394.
12. Foroozan R., Deramo V.A., Buono L.M., Jayamanne D.G., Sergott R.C., Danesh-Meyer H., et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 2003, 110:539-542.
13. Hayreh S.S. Management of ischemic optic neuropathies. Indian J Ophthalmol 2011, 59:123-136.
14. González-Gay M.A., Blanco R., Rodríguez-Valverde V., Martínez-Taboada V.M., Delgado-Rodriguez M., Figueroa M., et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998, 41:1497-1504.
15. Mukhtyar C., Guillevin L., Cid M.C., Dasgupta B., de Groot K., Gross W., et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009, 68:318-323.
16. Chevalet P., Barrier J.H., Pottier P., Magadur-Joly G., Pottier M.A., Hamidou M., et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164patients. J Rheumatol 2000, 27:1484-1491.
17. Sailler L., Lapeyre-Mestre M., Geffray L., Letellier P., Liozon E., de La Roque, et al. Adding hydroxychloroquine to prednisone does not improve the outcome in giant cell arteritis: a double blind randomized controlled trial [abstract]. Arthritis Rheum 2009, 1972.
18. Proven A., Gabriel S.E., Orces C., O'Fallon W.M., Hunder G.G. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003, 49:703-708.
19. Salvarani C., Cimino L., Macchioni P., Consonni D., Cantini F., Bajocchi G., et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 2005, 53:293-297.
20. Hoffman G.S., Cid M.C., Hellmann D.B., Guillevin L., Stone J.H., Schousboe J., et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002, 46:1309-1318.
21. Jover J.A., Hernández-García C., Morado I.C., Vargas E., Bañares A., Fernández-Gutiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 134:106-114.
22. Kyle V., Cawston T.E., Hazleman B.L. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up. Ann Rheum Dis 1989, 48:667-671.
23. Kyle V., Hazelman B.L. Stopping steroids in polymyalgia rheumatica and giant cell arteritis. BMJ 1990, 300:344-345.
24. Myklebust G., Gran J.T. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273patients. Scand J Rheumatol 2001, 30:260-267.
25. Liozon F., Vidal E., Boutros-Toni F., Gaches F., Loustaud-Ratti V., Liozon E., et al. [Clinical course of Horton disease. Apropos of 42cured patients]. Ann Med Interne (Paris) 1994, 145:223-229.
26. Dutoit A., Dubus V., Croccel L., Routier G., Godeau P. [Clinical and developmental aspects of Horton's disease. Retrospective study of 100cases]. Ann Cardiol Angeiol (Paris) 1988, 37:199-204.
27. Pugnet G., Sailler L., Astudillo L., Vernet J., Bennet A., Arlet P. [Frequency and risk factors of biological adrenal insufficiency screened by the 250microg Synacthene stimulation test after a prolonged course of systemic glucocorticoid therapy. A study of 100patients]. Rev Med Interne 2010, 31:332-336.
28. De Silva M., Hazleman B.L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986, 45:136-138.
29. Henes J.C., Mueller M., Pfannenberg C., Kanz L., Koetter I. Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol 2011, 29(1Suppl. 64):S43-S48.
30. Agard C., Barrier J.H. [Complicated Horton's syndrome: therapeutic modalities]. Presse Med 2004, 33:51-59.
31. Beyer C., Axmann R., Sahinbegovic E., Distler J.H., Manger B., Schett G., et al. Anti-interleukin 6receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 2011, 70:1874-1875.
32. Christidis D., Jain S., Gupta B.D. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep 2011, 2011. 10.1136/bcr.04.2011.4135.
33. Salvarani C., Magnani L., Catanoso M., Pipitone N., Versari A., Dardani L., et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012, 51:151-156.
34. Seitz M., Reichenbach S., Bonel H.M., Adler S., Wermelinger F., Villiger P.M. Rapid induction of remission in large vessel vasculitis by IL-6blockade. A case series. Swiss Med Wkly 2011, 141:w13156.
35. Unizony S., Arias-Urdaneta L., Miloslavsky E., Arvikar S., Khosroshahi A., Keroack B., et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 2012, 64:1720-1729.
36. Vinit J., Bielefeld P., Muller G., Besancenot J.F. Efficacy of tocilizumab in refractory giant cell arteritis. Joint Bone Spine 2012, 79:317-318.
37. Liozon F., Vidal E., Bonnetblanc J.M., Michel J.P., Weinbreck P., Bordessoule D., et al. [Disulon in the treatment of Horton's disease. Experience with 20patients]. Ann Med Interne (Paris) 1986, 137:299-306.
38. Liozon F., Vidal E., Barrier J. Does dapsone have a role in the treatment of temporal arteritis with regard to efficacy and toxicity?. Clin Exp Rheumatol 1993, 11:694-695.
39. Mazlumzadeh M., Hunder G.G., Easley K.A., Calamia K.T., Matteson E.L., Griffing W.L., et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006, 54:3310-3318.
40. Sailler L., Carreiro M., Ollier S., Juchet H., Delobel P., Ferrand D., et al. [Non-complicated Horton's disease: initial treatment with methylprednisolone 500mg/day bolus for three days followed by 20mg/day prednisone-equivalent. Evaluation of 15patients]. Rev Med Interne 2001, 22:1032-1038.
41. Spiera R.F., Mitnick H.J., Kupersmith M., Richmond M., Spiera H., Peterson M.G., et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001, 19:495-501.
42. Mahr A.D., Jover J.A., Spiera R.F., Hernández-García C., Fernández-Gutiérrez B., Lavalley M.P., et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007, 56:2789-2797.
43. Le Guennec P., Dromer C., Sixou L., Marc V., Coustals P., Fournié B. [Treatment of Horton disease. Value of synthetic antimalarials. Apropos of a retrospective study of 36patients]. Rev Rhum Ed Fr 1994, 61:485-490.
44. David-Chaussé J., Dehais J., Leman A. [Results of a regional survey on the treatment of rhizomelic pseudopolyarthritis and temporal arteritis. Apropos of 242cases treated by various modalities with synthetic antimalarials, corticoids and non-steroidal anti-inflammatory agents]. Rev Rhum Mal Osteoartic 1983, 50:563-571.
45. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., Merkel P.A., Weyand C.M., Stone J.H., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007, 146:621-630.
46. Mariette X., Hachulla E., Larroche C., Puéchal X., Maurier F., de Wazieres B., et al. Results of a randomized controlled study of adalimumab for steroid sparing in patients with giant-cell arteritis. Arthritis Rheum 2011, 63:S589.
47. Martínez-Taboada V.M., Rodríguez-Valverde V., Carreño L., López-Longo J., Figueroa M., Belzunegui J., et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008, 67:625-630.
48. Martinez-Taboada V.M., Alvarez L., RuizSoto M., Marin-Vidalled M.J., Lopez-Hoyos M. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine 2008, 44:207-220.
49. Nishimoto N., Nakahara H., Yoshio-Hoshino N., Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6receptor antibody. Arthritis Rheum 2008, 58:1197-1200.
50. Sciascia S., Rossi D., Roccatello D. Interleukin 6blockade as steroid-sparing treatment for 2patients with giant cell arteritis. J Rheumatol 2011, 38:2080-2081.
51. Le Page L., Duhaut P., Seydoux D., Bosshard S., Ecochard R., Abbas F., et al. [Incidence of cardiovascular events in giant cell arteritis: preliminary results of a prospective double cohort study (GRACG)]. Rev Med Interne 2006, 27:98-105.
52. Gonzalez-Gay M.A., Pineiro A., Gomez-Gigirey A., Garcia-Porrua C., Pego-Reigosa R., Dierssen-Sotos T., et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004, 83:342-347.
53. Wei L., MacDonald T.M., Walker B.R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004, 141:764-770.
54. Souverein P.C., Berard A., Van Staa T.P., Cooper C., Egberts A.C., Leufkens H.G., et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004, 90:859-865.
55. Maradit Kremers H., Reinalda M.S., Crowson C.S., Davis J.M., Hunder G.G., Gabriel S.E. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum 2007, 57:279-286.
56. Weyand CM, Goronzy JJ. Pathogenic mechanisms in giant cell arteritis. Cleve Clin J Med 2002;69(Suppl. 2):SII28-32-SII28-32.
57. Nesher G., Berkun Y., Mates M., Baras M., Rubinow A., Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004, 50:1332-1337.
58. Nesher G., Berkun Y., Mates M., Baras M., Nesher R., Rubinow A., et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine 2004, 83:114-122.
59. Lee M.S., Smith S.D., Galor A., Hoffman G.S. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006, 54:3306-3309.
60. Mackie S.L., Dasgupta B., Hordon L., Gough A., Green M., Hollywood J., et al. Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors. Rheumatology (Oxford) 2011, 50:2014-2022.
61. Gonzalez-Gay M.A., Vazquez-Rodriguez T.R., Gomez-Acebo I., Pego-Reigosa R., Lopez-Diaz M.J., Vazquez-Triñanes M.C., et al. Strokes at time of disease diagnosis in a series of 287patients with biopsy-proven giant cell arteritis. Medicine 2009, 88:227-235.
62. Narváez J., Bernad B., Nolla J.M., Valverde J. Statin therapy does not seem to benefit giant cell arteritis. Semin Arthritis Rheum 2007, 36:322-327.
63. García-Martínez A., Hernández-Rodríguez J., Grau J.M., Cid M.C. Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. Arthritis Rheum 2004, 51:674-678.